Literature DB >> 1394199

Estrogen receptor-directed radiotoxicity with Auger electrons: specificity and mean lethal dose.

E R DeSombre1, B Shafii, R N Hanson, P C Kuivanen, A Hughes.   

Abstract

To assess the feasibility of using estrogen receptor-directed therapy with Auger electron-emitting ligands for therapy of estrogen receptor (ER)-containing cancers, we synthesized and evaluated the radiotoxicity of several 123I-labeled estrogens to specifically kill ER+ cells in culture. Auger electrons have been previously shown to be of short range, generally less than the dimensions of a cell, so that to use them therapeutically a mechanism is needed to deliver the Auger electron-emitting nuclide to the vicinity of the DNA. Since it is now well established that the estrogen receptor, when bound to estrogen, forms a high affinity association with distinct estrogen response elements in the DNA, we wished to test the hypothesis that a short exposure of cells to a 123I-labeled estrogen would be specifically radiotoxic to ER+ cells, and that the decays per cell needed for cell killing would be compatible with reasonable levels of receptor occupancy. Using the halodestannylation reaction with tributyl tin precursors of several estrogens and commercially available iodine-123, we prepared the iodoestrogens, E-17 alpha(-)[123I]-iodo-11 beta-methoxyestradiol and 2(-)[123I]iodo-1,1-bis(4-hydroxyphenyl)--2-phenylethylene, at high specific activities, in several cases at essentially the specific activity of 123I itself, 240,000 Ci/mmol. When various concentrations of either of the 123I-labeled estrogens were incubated for 1 h with a subline of ER+ Chinese hamster ovary cells and the washed cells plated for survival assays, a dose-dependent, unlabeled estradiol-inhibitable reduction in survival was observed. In contrast, Chinese hamster ovary cells not expressing estrogen receptor showed little sensitivity to the radiotoxicity of the 123I-labeled estrogens. Calculations based on the assayed residence time of the iodoestrogens in the cells indicate that several hundred decays per cell are sufficient to kill cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1394199

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Evaluation of a bromine-76-labeled progestin 16alpha,17alpha-dioxolane for breast tumor imaging and radiotherapy: in vivo biodistribution and metabolic stability studies.

Authors:  Dong Zhou; Terry L Sharp; Nicole M Fettig; Hsiaoju Lee; Jason S Lewis; John A Katzenellenbogen; Michael J Welch
Journal:  Nucl Med Biol       Date:  2008-06-30       Impact factor: 2.408

2.  Radiolabeled cyclosaligenyl monophosphates of 5-iodo-2'-deoxyuridine, 5-iodo-3'-fluoro-2',3'-dideoxyuridine, and 3'-fluorothymidine for molecular radiotherapy of cancer: synthesis and biological evaluation.

Authors:  Zbigniew P Kortylewicz; Yu Kimura; Kotaro Inoue; Elizabeth Mack; Janina Baranowska-Kortylewicz
Journal:  J Med Chem       Date:  2012-03-08       Impact factor: 7.446

3.  Incorporation of iododeoxyuridine in multicellular glioma spheroids: implications for DNA-targeted radiotherapy using Auger electron emitters.

Authors:  A Neshasteh-Riz; W J Angerson; J R Reeves; G Smith; R Rampling; R J Mairs
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 4.  Subcellular Targeting of Theranostic Radionuclides.

Authors:  Bas M Bavelaar; Boon Q Lee; Martin R Gill; Nadia Falzone; Katherine A Vallis
Journal:  Front Pharmacol       Date:  2018-09-04       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.